These findings suggest that SGLT2 inhibitors may influence disease trajectory even before the onset of symptomatic severe AS, potentially through modulation of the fibrotic and inflammatory pathways identified in the BIO-AS study [118]. The gene discussed is SLC5A2; the disease is aortic stenosis.